The global MET Inhibitor Drugs market size was valued at US$ 789 million in 2024 and is projected to reach US$ 1.56 billion by 2030, at a CAGR of 12.0% during the forecast period 2024-2030.
United States MET Inhibitor Drugs market size was valued at US$ 289 million in 2024 and is projected to reach US$ 545 million by 2030, at a CAGR of 11.2% during the forecast period 2024-2030.
Report Overview
This report provides a deep insight into the global MET Inhibitor Drugs market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
MET inhibitor drugs target the MET (mesenchymal-epithelial transition) receptor tyrosine kinase, which plays a crucial role in cell growth, survival, and metastasis. Dysregulation of the MET pathway is associated with various cancers, making it an important therapeutic target in oncology. MET inhibitors are used to block this signaling pathway and inhibit tumor growth.
Key Information on MET Inhibitors
-
Mechanism of Action: MET inhibitors work by blocking the MET receptor or its ligand, hepatocyte growth factor (HGF). When MET is overexpressed, mutated, or aberrantly activated, it promotes cancer cell proliferation, survival, angiogenesis (new blood vessel formation), and metastasis. MET inhibitors can prevent these cancer-promoting activities.
-
Types of MET Inhibitors:
- Selective MET Inhibitors: These drugs specifically target the MET receptor and its signaling pathway.
- Example: Capmatinib (Tabrecta) – approved for non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutations.
- Multi-Kinase Inhibitors: These drugs target several tyrosine kinases, including MET.
- Example: Crizotinib (Xalkori) – initially developed as an ALK inhibitor but also targets MET, used in certain lung cancers.
-
Approved MET Inhibitors:
- Capmatinib (Tabrecta): Approved by the FDA for NSCLC patients with MET exon 14 skipping mutations.
- Tepotinib (Tepmetko): Another FDA-approved drug for MET exon 14 skipping mutation-positive NSCLC.
- Savolitinib: Approved in China for patients with MET-driven papillary renal cell carcinoma.
-
Clinical Applications:
- Non-Small Cell Lung Cancer (NSCLC): MET inhibitors are most commonly used in NSCLC with MET gene mutations or amplification. MET exon 14 skipping mutations occur in about 3-4% of NSCLC cases.
- Renal Cell Carcinoma (RCC): Savolitinib is used for treating papillary renal cell carcinoma driven by MET alterations.
- Other Cancer Types: MET inhibitors are being investigated in clinical trials for gastric cancer, colorectal cancer, and hepatocellular carcinoma, where MET dysregulation plays a role.
-
Resistance Mechanisms: Some cancers develop resistance to MET inhibitors due to secondary mutations in MET, activation of compensatory pathways (such as EGFR or PI3K), or histological transformation. Research is ongoing to understand and overcome these resistance mechanisms.
-
Side Effects: Common side effects of MET inhibitors include:
- Fatigue
- Nausea
- Diarrhea
- Edema (swelling)
- Liver function abnormalities
- Interstitial lung disease (rare but serious)
-
Ongoing Research: Numerous clinical trials are exploring the use of MET inhibitors in combination with other targeted therapies, immunotherapies, and chemotherapies. Combination therapies aim to enhance treatment efficacy and delay or prevent resistance.
Challenges and Future Directions
- Biomarker Development: To identify the right patients for MET inhibitors, biomarkers like MET amplification, exon 14 skipping mutations, and protein overexpression need to be accurately detected.
- Overcoming Resistance: Strategies to overcome resistance, such as combining MET inhibitors with other pathway inhibitors (EGFR, VEGF), are key areas of research.
- Broader Cancer Applications: Although MET inhibitors show promise in specific cancers, more work is needed to determine their effectiveness in broader cancer types and settings.
MET inhibitors are a promising class of drugs in targeted cancer therapy, especially for patients with MET-driven tumors. Ongoing studies are refining their use and exploring their potential in combination treatments for various cancers.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global MET Inhibitor Drugs Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the MET Inhibitor Drugs market in any manner.
Global MET Inhibitor Drugs Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
- Abbott Laboratories
- Johnson and Johnson
- Novartis International AG
- Eli Lilly and Company
- Pfizer Inc., Merck & Co.
- Takeda Pharmaceutical Company
- GlaxosmithKline plc
- Amgen Inc.
- Bristol Myers Squibb
- Daiichi Sankyo Company, Limited
- Including or Excluding key companies relevant to your analysis.
Market Segmentation (by Type)
- C-Met Biological Inhibitors
- Small Molecule C-Met Inhibitors
- C-Met Antagonist Antibodies
- HGF Antagonist Antibodies
- Kringle Variant Antagonists
Market Segmentation (by Application)
- Hospital Pharmacies
- Retail Pharmacies
- Others
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the MET Inhibitor Drugs Market
- Overview of the regional outlook of the MET Inhibitor Drugs Market:
Key Reasons to Buy this Report:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value (USD Billion) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porters five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 6-month post-sales analyst support
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the MET Inhibitor Drugs Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
TABLE OF CONTENTS
Table of Contents
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of MET Inhibitor Drugs
1.2 Key Market Segments
1.2.1 MET Inhibitor Drugs Segment by Type
1.2.2 MET Inhibitor Drugs Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 MET Inhibitor Drugs Market Overview
2.1 Global Market Overview
2.1.1 Global MET Inhibitor Drugs Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global MET Inhibitor Drugs Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 MET Inhibitor Drugs Market Competitive Landscape
3.1 Global MET Inhibitor Drugs Sales by Manufacturers (2019-2024)
3.2 Global MET Inhibitor Drugs Revenue Market Share by Manufacturers (2019-2024)
3.3 MET Inhibitor Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global MET Inhibitor Drugs Average Price by Manufacturers (2019-2024)
3.5 Manufacturers MET Inhibitor Drugs Sales Sites, Area Served, Product Type
3.6 MET Inhibitor Drugs Market Competitive Situation and Trends
3.6.1 MET Inhibitor Drugs Market Concentration Rate
3.6.2 Global 5 and 10 Largest MET Inhibitor Drugs Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 MET Inhibitor Drugs Industry Chain Analysis
4.1 MET Inhibitor Drugs Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of MET Inhibitor Drugs Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 MET Inhibitor Drugs Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global MET Inhibitor Drugs Sales Market Share by Type (2019-2024)
6.3 Global MET Inhibitor Drugs Market Size Market Share by Type (2019-2024)
6.4 Global MET Inhibitor Drugs Price by Type (2019-2024)
7 MET Inhibitor Drugs Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global MET Inhibitor Drugs Market Sales by Application (2019-2024)
7.3 Global MET Inhibitor Drugs Market Size (M USD) by Application (2019-2024)
7.4 Global MET Inhibitor Drugs Sales Growth Rate by Application (2019-2024)
8 MET Inhibitor Drugs Market Segmentation by Region
8.1 Global MET Inhibitor Drugs Sales by Region
8.1.1 Global MET Inhibitor Drugs Sales by Region
8.1.2 Global MET Inhibitor Drugs Sales Market Share by Region
8.2 North America
8.2.1 North America MET Inhibitor Drugs Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe MET Inhibitor Drugs Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific MET Inhibitor Drugs Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America MET Inhibitor Drugs Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa MET Inhibitor Drugs Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Key Companies Profile
9.1 Abbott Laboratories
9.1.1 Abbott Laboratories MET Inhibitor Drugs Basic Information
9.1.2 Abbott Laboratories MET Inhibitor Drugs Product Overview
9.1.3 Abbott Laboratories MET Inhibitor Drugs Product Market Performance
9.1.4 Abbott Laboratories Business Overview
9.1.5 Abbott Laboratories MET Inhibitor Drugs SWOT Analysis
9.1.6 Abbott Laboratories Recent Developments
9.2 Johnson and Johnson
9.2.1 Johnson and Johnson MET Inhibitor Drugs Basic Information
9.2.2 Johnson and Johnson MET Inhibitor Drugs Product Overview
9.2.3 Johnson and Johnson MET Inhibitor Drugs Product Market Performance
9.2.4 Johnson and Johnson Business Overview
9.2.5 Johnson and Johnson MET Inhibitor Drugs SWOT Analysis
9.2.6 Johnson and Johnson Recent Developments
9.3 Novartis International AG
9.3.1 Novartis International AG MET Inhibitor Drugs Basic Information
9.3.2 Novartis International AG MET Inhibitor Drugs Product Overview
9.3.3 Novartis International AG MET Inhibitor Drugs Product Market Performance
9.3.4 Novartis International AG MET Inhibitor Drugs SWOT Analysis
9.3.5 Novartis International AG Business Overview
9.3.6 Novartis International AG Recent Developments
9.4 Eli Lilly and Company
9.4.1 Eli Lilly and Company MET Inhibitor Drugs Basic Information
9.4.2 Eli Lilly and Company MET Inhibitor Drugs Product Overview
9.4.3 Eli Lilly and Company MET Inhibitor Drugs Product Market Performance
9.4.4 Eli Lilly and Company Business Overview
9.4.5 Eli Lilly and Company Recent Developments
9.5 Pfizer Inc., Merck and Co.
9.5.1 Pfizer Inc., Merck and Co. MET Inhibitor Drugs Basic Information
9.5.2 Pfizer Inc., Merck and Co. MET Inhibitor Drugs Product Overview
9.5.3 Pfizer Inc., Merck and Co. MET Inhibitor Drugs Product Market Performance
9.5.4 Pfizer Inc., Merck and Co. Business Overview
9.5.5 Pfizer Inc., Merck and Co. Recent Developments
9.6 Takeda Pharmaceutical Company
9.6.1 Takeda Pharmaceutical Company MET Inhibitor Drugs Basic Information
9.6.2 Takeda Pharmaceutical Company MET Inhibitor Drugs Product Overview
9.6.3 Takeda Pharmaceutical Company MET Inhibitor Drugs Product Market Performance
9.6.4 Takeda Pharmaceutical Company Business Overview
9.6.5 Takeda Pharmaceutical Company Recent Developments
9.7 GlaxosmithKline plc
9.7.1 GlaxosmithKline plc MET Inhibitor Drugs Basic Information
9.7.2 GlaxosmithKline plc MET Inhibitor Drugs Product Overview
9.7.3 GlaxosmithKline plc MET Inhibitor Drugs Product Market Performance
9.7.4 GlaxosmithKline plc Business Overview
9.7.5 GlaxosmithKline plc Recent Developments
9.8 Amgen Inc.
9.8.1 Amgen Inc. MET Inhibitor Drugs Basic Information
9.8.2 Amgen Inc. MET Inhibitor Drugs Product Overview
9.8.3 Amgen Inc. MET Inhibitor Drugs Product Market Performance
9.8.4 Amgen Inc. Business Overview
9.8.5 Amgen Inc. Recent Developments
9.9 Bristol Myers Squibb
9.9.1 Bristol Myers Squibb MET Inhibitor Drugs Basic Information
9.9.2 Bristol Myers Squibb MET Inhibitor Drugs Product Overview
9.9.3 Bristol Myers Squibb MET Inhibitor Drugs Product Market Performance
9.9.4 Bristol Myers Squibb Business Overview
9.9.5 Bristol Myers Squibb Recent Developments
9.10 Daiichi Sankyo Company, Limited
9.10.1 Daiichi Sankyo Company, Limited MET Inhibitor Drugs Basic Information
9.10.2 Daiichi Sankyo Company, Limited MET Inhibitor Drugs Product Overview
9.10.3 Daiichi Sankyo Company, Limited MET Inhibitor Drugs Product Market Performance
9.10.4 Daiichi Sankyo Company, Limited Business Overview
9.10.5 Daiichi Sankyo Company, Limited Recent Developments
10 MET Inhibitor Drugs Market Forecast by Region
10.1 Global MET Inhibitor Drugs Market Size Forecast
10.2 Global MET Inhibitor Drugs Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe MET Inhibitor Drugs Market Size Forecast by Country
10.2.3 Asia Pacific MET Inhibitor Drugs Market Size Forecast by Region
10.2.4 South America MET Inhibitor Drugs Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of MET Inhibitor Drugs by Country
11 Forecast Market by Type and by Application (2025-2030)
11.1 Global MET Inhibitor Drugs Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of MET Inhibitor Drugs by Type (2025-2030)
11.1.2 Global MET Inhibitor Drugs Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of MET Inhibitor Drugs by Type (2025-2030)
11.2 Global MET Inhibitor Drugs Market Forecast by Application (2025-2030)
11.2.1 Global MET Inhibitor Drugs Sales (Kilotons) Forecast by Application
11.2.2 Global MET Inhibitor Drugs Market Size (M USD) Forecast by Application (2025-2030)
12 Conclusion and Key Findings
LIST OF TABLES & FIGURES
List of Tables
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. MET Inhibitor Drugs Market Size Comparison by Region (M USD)
Table 5. Global MET Inhibitor Drugs Sales (Kilotons) by Manufacturers (2019-2024)
Table 6. Global MET Inhibitor Drugs Sales Market Share by Manufacturers (2019-2024)
Table 7. Global MET Inhibitor Drugs Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global MET Inhibitor Drugs Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in MET Inhibitor Drugs as of 2022)
Table 10. Global Market MET Inhibitor Drugs Average Price (USD/Ton) of Key Manufacturers (2019-2024)
Table 11. Manufacturers MET Inhibitor Drugs Sales Sites and Area Served
Table 12. Manufacturers MET Inhibitor Drugs Product Type
Table 13. Global MET Inhibitor Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of MET Inhibitor Drugs
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. MET Inhibitor Drugs Market Challenges
Table 22. Global MET Inhibitor Drugs Sales by Type (Kilotons)
Table 23. Global MET Inhibitor Drugs Market Size by Type (M USD)
Table 24. Global MET Inhibitor Drugs Sales (Kilotons) by Type (2019-2024)
Table 25. Global MET Inhibitor Drugs Sales Market Share by Type (2019-2024)
Table 26. Global MET Inhibitor Drugs Market Size (M USD) by Type (2019-2024)
Table 27. Global MET Inhibitor Drugs Market Size Share by Type (2019-2024)
Table 28. Global MET Inhibitor Drugs Price (USD/Ton) by Type (2019-2024)
Table 29. Global MET Inhibitor Drugs Sales (Kilotons) by Application
Table 30. Global MET Inhibitor Drugs Market Size by Application
Table 31. Global MET Inhibitor Drugs Sales by Application (2019-2024) & (Kilotons)
Table 32. Global MET Inhibitor Drugs Sales Market Share by Application (2019-2024)
Table 33. Global MET Inhibitor Drugs Sales by Application (2019-2024) & (M USD)
Table 34. Global MET Inhibitor Drugs Market Share by Application (2019-2024)
Table 35. Global MET Inhibitor Drugs Sales Growth Rate by Application (2019-2024)
Table 36. Global MET Inhibitor Drugs Sales by Region (2019-2024) & (Kilotons)
Table 37. Global MET Inhibitor Drugs Sales Market Share by Region (2019-2024)
Table 38. North America MET Inhibitor Drugs Sales by Country (2019-2024) & (Kilotons)
Table 39. Europe MET Inhibitor Drugs Sales by Country (2019-2024) & (Kilotons)
Table 40. Asia Pacific MET Inhibitor Drugs Sales by Region (2019-2024) & (Kilotons)
Table 41. South America MET Inhibitor Drugs Sales by Country (2019-2024) & (Kilotons)
Table 42. Middle East and Africa MET Inhibitor Drugs Sales by Region (2019-2024) & (Kilotons)
Table 43. Abbott Laboratories MET Inhibitor Drugs Basic Information
Table 44. Abbott Laboratories MET Inhibitor Drugs Product Overview
Table 45. Abbott Laboratories MET Inhibitor Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 46. Abbott Laboratories Business Overview
Table 47. Abbott Laboratories MET Inhibitor Drugs SWOT Analysis
Table 48. Abbott Laboratories Recent Developments
Table 49. Johnson and Johnson MET Inhibitor Drugs Basic Information
Table 50. Johnson and Johnson MET Inhibitor Drugs Product Overview
Table 51. Johnson and Johnson MET Inhibitor Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 52. Johnson and Johnson Business Overview
Table 53. Johnson and Johnson MET Inhibitor Drugs SWOT Analysis
Table 54. Johnson and Johnson Recent Developments
Table 55. Novartis International AG MET Inhibitor Drugs Basic Information
Table 56. Novartis International AG MET Inhibitor Drugs Product Overview
Table 57. Novartis International AG MET Inhibitor Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 58. Novartis International AG MET Inhibitor Drugs SWOT Analysis
Table 59. Novartis International AG Business Overview
Table 60. Novartis International AG Recent Developments
Table 61. Eli Lilly and Company MET Inhibitor Drugs Basic Information
Table 62. Eli Lilly and Company MET Inhibitor Drugs Product Overview
Table 63. Eli Lilly and Company MET Inhibitor Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 64. Eli Lilly and Company Business Overview
Table 65. Eli Lilly and Company Recent Developments
Table 66. Pfizer Inc., Merck and Co. MET Inhibitor Drugs Basic Information
Table 67. Pfizer Inc., Merck and Co. MET Inhibitor Drugs Product Overview
Table 68. Pfizer Inc., Merck and Co. MET Inhibitor Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 69. Pfizer Inc., Merck and Co. Business Overview
Table 70. Pfizer Inc., Merck and Co. Recent Developments
Table 71. Takeda Pharmaceutical Company MET Inhibitor Drugs Basic Information
Table 72. Takeda Pharmaceutical Company MET Inhibitor Drugs Product Overview
Table 73. Takeda Pharmaceutical Company MET Inhibitor Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 74. Takeda Pharmaceutical Company Business Overview
Table 75. Takeda Pharmaceutical Company Recent Developments
Table 76. GlaxosmithKline plc MET Inhibitor Drugs Basic Information
Table 77. GlaxosmithKline plc MET Inhibitor Drugs Product Overview
Table 78. GlaxosmithKline plc MET Inhibitor Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 79. GlaxosmithKline plc Business Overview
Table 80. GlaxosmithKline plc Recent Developments
Table 81. Amgen Inc. MET Inhibitor Drugs Basic Information
Table 82. Amgen Inc. MET Inhibitor Drugs Product Overview
Table 83. Amgen Inc. MET Inhibitor Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 84. Amgen Inc. Business Overview
Table 85. Amgen Inc. Recent Developments
Table 86. Bristol Myers Squibb MET Inhibitor Drugs Basic Information
Table 87. Bristol Myers Squibb MET Inhibitor Drugs Product Overview
Table 88. Bristol Myers Squibb MET Inhibitor Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 89. Bristol Myers Squibb Business Overview
Table 90. Bristol Myers Squibb Recent Developments
Table 91. Daiichi Sankyo Company, Limited MET Inhibitor Drugs Basic Information
Table 92. Daiichi Sankyo Company, Limited MET Inhibitor Drugs Product Overview
Table 93. Daiichi Sankyo Company, Limited MET Inhibitor Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 94. Daiichi Sankyo Company, Limited Business Overview
Table 95. Daiichi Sankyo Company, Limited Recent Developments
Table 96. Global MET Inhibitor Drugs Sales Forecast by Region (2025-2030) & (Kilotons)
Table 97. Global MET Inhibitor Drugs Market Size Forecast by Region (2025-2030) & (M USD)
Table 98. North America MET Inhibitor Drugs Sales Forecast by Country (2025-2030) & (Kilotons)
Table 99. North America MET Inhibitor Drugs Market Size Forecast by Country (2025-2030) & (M USD)
Table 100. Europe MET Inhibitor Drugs Sales Forecast by Country (2025-2030) & (Kilotons)
Table 101. Europe MET Inhibitor Drugs Market Size Forecast by Country (2025-2030) & (M USD)
Table 102. Asia Pacific MET Inhibitor Drugs Sales Forecast by Region (2025-2030) & (Kilotons)
Table 103. Asia Pacific MET Inhibitor Drugs Market Size Forecast by Region (2025-2030) & (M USD)
Table 104. South America MET Inhibitor Drugs Sales Forecast by Country (2025-2030) & (Kilotons)
Table 105. South America MET Inhibitor Drugs Market Size Forecast by Country (2025-2030) & (M USD)
Table 106. Middle East and Africa MET Inhibitor Drugs Consumption Forecast by Country (2025-2030) & (Units)
Table 107. Middle East and Africa MET Inhibitor Drugs Market Size Forecast by Country (2025-2030) & (M USD)
Table 108. Global MET Inhibitor Drugs Sales Forecast by Type (2025-2030) & (Kilotons)
Table 109. Global MET Inhibitor Drugs Market Size Forecast by Type (2025-2030) & (M USD)
Table 110. Global MET Inhibitor Drugs Price Forecast by Type (2025-2030) & (USD/Ton)
Table 111. Global MET Inhibitor Drugs Sales (Kilotons) Forecast by Application (2025-2030)
Table 112. Global MET Inhibitor Drugs Market Size Forecast by Application (2025-2030) & (M USD)
List of Figures
Figure 1. Product Picture of MET Inhibitor Drugs
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global MET Inhibitor Drugs Market Size (M USD), 2019-2030
Figure 5. Global MET Inhibitor Drugs Market Size (M USD) (2019-2030)
Figure 6. Global MET Inhibitor Drugs Sales (Kilotons) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. MET Inhibitor Drugs Market Size by Country (M USD)
Figure 11. MET Inhibitor Drugs Sales Share by Manufacturers in 2023
Figure 12. Global MET Inhibitor Drugs Revenue Share by Manufacturers in 2023
Figure 13. MET Inhibitor Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market MET Inhibitor Drugs Average Price (USD/Ton) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by MET Inhibitor Drugs Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global MET Inhibitor Drugs Market Share by Type
Figure 18. Sales Market Share of MET Inhibitor Drugs by Type (2019-2024)
Figure 19. Sales Market Share of MET Inhibitor Drugs by Type in 2023
Figure 20. Market Size Share of MET Inhibitor Drugs by Type (2019-2024)
Figure 21. Market Size Market Share of MET Inhibitor Drugs by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global MET Inhibitor Drugs Market Share by Application
Figure 24. Global MET Inhibitor Drugs Sales Market Share by Application (2019-2024)
Figure 25. Global MET Inhibitor Drugs Sales Market Share by Application in 2023
Figure 26. Global MET Inhibitor Drugs Market Share by Application (2019-2024)
Figure 27. Global MET Inhibitor Drugs Market Share by Application in 2023
Figure 28. Global MET Inhibitor Drugs Sales Growth Rate by Application (2019-2024)
Figure 29. Global MET Inhibitor Drugs Sales Market Share by Region (2019-2024)
Figure 30. North America MET Inhibitor Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 31. North America MET Inhibitor Drugs Sales Market Share by Country in 2023
Figure 32. U.S. MET Inhibitor Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 33. Canada MET Inhibitor Drugs Sales (Kilotons) and Growth Rate (2019-2024)
Figure 34. Mexico MET Inhibitor Drugs Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe MET Inhibitor Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 36. Europe MET Inhibitor Drugs Sales Market Share by Country in 2023
Figure 37. Germany MET Inhibitor Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 38. France MET Inhibitor Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 39. U.K. MET Inhibitor Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 40. Italy MET Inhibitor Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 41. Russia MET Inhibitor Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 42. Asia Pacific MET Inhibitor Drugs Sales and Growth Rate (Kilotons)
Figure 43. Asia Pacific MET Inhibitor Drugs Sales Market Share by Region in 2023
Figure 44. China MET Inhibitor Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 45. Japan MET Inhibitor Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 46. South Korea MET Inhibitor Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 47. India MET Inhibitor Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 48. Southeast Asia MET Inhibitor Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 49. South America MET Inhibitor Drugs Sales and Growth Rate (Kilotons)
Figure 50. South America MET Inhibitor Drugs Sales Market Share by Country in 2023
Figure 51. Brazil MET Inhibitor Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 52. Argentina MET Inhibitor Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 53. Columbia MET Inhibitor Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 54. Middle East and Africa MET Inhibitor Drugs Sales and Growth Rate (Kilotons)
Figure 55. Middle East and Africa MET Inhibitor Drugs Sales Market Share by Region in 2023
Figure 56. Saudi Arabia MET Inhibitor Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 57. UAE MET Inhibitor Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 58. Egypt MET Inhibitor Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 59. Nigeria MET Inhibitor Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 60. South Africa MET Inhibitor Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 61. Global MET Inhibitor Drugs Sales Forecast by Volume (2019-2030) & (Kilotons)
Figure 62. Global MET Inhibitor Drugs Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global MET Inhibitor Drugs Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global MET Inhibitor Drugs Market Share Forecast by Type (2025-2030)
Figure 65. Global MET Inhibitor Drugs Sales Forecast by Application (2025-2030)
Figure 66. Global MET Inhibitor Drugs Market Share Forecast by Application (2025-2030)
